12:00 AM
 | 
Nov 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ganetespib: Updated Phase IIb data

Synta reported 1-year follow-up data from 178 stage IIIB/IV NSCLC adenocarcinoma patients who were enrolled >6 months after diagnosis of disease - the population Synta chose for Phase III testing with ganetespib - in the open-label Phase IIb portion of the international Phase IIb/III GALAXY-1 trial showing that ganetespib plus docetaxel as second-line treatment led to a median OS of 10.7 months vs. 7.4 months for docetaxel alone (unadjusted HR=0.75, p=0.065). Additionally, ganetespib plus docetaxel led to a median PFS of 5.3 months in the subgroup vs. 3.4 months for docetaxel alone (unadjusted HR=0.73, p=0.031). Patients received 150 mg/m 2 ganetespib on days 1 and 15 plus 75 mg/m 2 docetaxel on day 1 of a 21-day cycle. Data were presented at...

Read the full 588 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >